Glatiramer Acetate Injection, Solution
Product Images NDC 0378-6961

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Glatiramer Acetate (NDC 0378-6961). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Glatiramer Acetate Structural Formula (5cd25695 8a5c 48b6 Bd73 86a48de41493 01)

Chemical structure of Glatiramer (Glatiramer Acetate) shown as a formula with amino acid residues including Glu, Ala, Lys, and Tyr, representing its polymeric composition.*

FDA Label Image

Figure 1: Time To Second Exacerbation (5cd25695 8a5c 48b6 Bd73 86a48de41493 02)

A Kaplan-Meier curve comparing the percentage of patients experiencing second exacerbation over time between Glatiramer Acetate 40 mg/mL injection and placebo groups. The graph shows cumulative incidence on the y-axis over approximately 1080 days on the x-axis, with Glatiramer Acetate having a lower rate of second exacerbations compared to placebo.*

FDA Label Image

Figure 2: Median Cumulative Number Of Gd-enhancing Lesions (5cd25695 8a5c 48b6 Bd73 86a48de41493 03)

A line chart comparing the median cumulative number of enhancing lesions over 9 months between Glatiramer Acetate and placebo groups. The x-axis represents months from 0 to 9, and the y-axis shows the median cumulative number of enhancing lesions, with Glatiramer Acetate consistently showing fewer lesions than placebo over time.*

FDA Label Image

Instructions For Use Figure A (Image 01)

An instructional diagram illustrating components used for subcutaneous injection of Glatiramer Acetate 40 mg/mL. It shows a sharps disposal container, syringe in a blister package, cotton balls, alcohol wipes, and an injection diary used to track doses.*

FDA Label Image

Instructions For Use Figure B (Image 02)

An instructional illustration labeled Figure B shows a person holding a syringe with one hand while using the other hand to remove a cap or cover from the needle, likely preparing the injection device for use.*

FDA Label Image

Instructions For Use Figure C (Image 03)

An instructional diagram showing recommended subcutaneous injection sites for Glatiramer Acetate injection, solution 40 mg/mL. It illustrates areas on the abdomen (avoiding 2 inches around the belly button), back of hips and arms (fleshy areas below the waist and upper back portion of arms), upper back portion of arms, and thighs (about 2 inches above the knee and 2 inches below the groin).*

FDA Label Image

Instructions For Use Figure D (Image 04)

An instructional illustration showing the use of a hand to pinch the skin, presumably for subcutaneous injection preparation. The image is labeled as Figure D, demonstrating the proper technique for administering an injection beneath the skin.*

FDA Label Image

Instructions For Use Figure E (Image 05)

An instructional illustration in three panels demonstrating subcutaneous injection technique using a syringe. The panels show proper hand positioning and syringe insertion steps for administering an injection. No specific product branding or labeling is visible.*

FDA Label Image

Instructions For Use Figure F (Image 06)

An instructional illustration showing a hand pinching the skin, likely demonstrating how to prepare an injection site for subcutaneous administration.*

FDA Label Image

Instructions For Use Figure G (Image 07)

An instructional illustration showing a hand holding a syringe injecting a solution subcutaneously into the outer thigh of the opposite leg. The figure is labeled as "Figure G" and demonstrates proper injection technique for a subcutaneous injection.*

FDA Label Image

Instructions For Use Figure H (Image 08)

An instructional illustration showing a person administering a subcutaneous injection to the abdomen using a syringe. The diagram focuses on hand placement with one hand stabilizing the injection site and the other holding the syringe.*

FDA Label Image

Instructions For Use Figure I (Image 09)

An instructional illustration showing a hand holding a syringe, preparing to inject a solution subcutaneously into the skin of another hand. The image demonstrates the correct angle and technique for administering the injection.*

FDA Label Image

Instructions For Use Figure J (Image 10)

Instructional illustration showing a person administering a subcutaneous injection with a syringe on the outer area of the upper arm, depicting the injection technique for glatiramer acetate solution.*

FDA Label Image

Instructions For Use Figure K (Image 11)

An instructional illustration labeled 'Figure K' showing a hand pinching the skin on the arm, demonstrating a technique for subcutaneous injection. The image focuses on the proper method to prepare the injection site for a subcutaneous shot.*

FDA Label Image

Instructions For Use Figure L (Image 12)

An instructional or safety illustration showing a sharps disposal container with a biohazard symbol. The container is intended for safe disposal of medical needles or other sharp objects, likely related to subcutaneous injection use.*

FDA Label Image

Glatiramer Acetate Injection 40 mg/ml Carton Label (Image 13)

Packaging label for Glatiramer Acetate Injection 40 mg/mL by Mylan Pharmaceuticals Inc. The label indicates a subcutaneous injection for prescription use. The carton contains 12 single-dose pre-filled syringes with fixed 1/2 inch 29 gauge needles. Directions note administration three times a week. Storage instructions and manufacturing details are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.